Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RNAi Giant Alnylam Says Alliances with Japanese Pharmas Well Underway

This article was originally published in PharmAsia News

Executive Summary

TOKYO - An executive from Massachusetts-based biotech Alnylam says its RNAi alliances with Takeda and Kyowa Hakko Kirin are well underway
Advertisement

Related Content

Takeda Research Investment’s Graeme Martin On Corporate Venture Capital’s Role in Developing Next-Generation Biologics: An Interview With PharmAsia News(Part 2 of 2)
Takeda Research Investment’s Graeme Martin On Corporate Venture Capital’s Role in Developing Next-Generation Biologics: An Interview With PharmAsia News(Part 2 of 2)
Corporate Venture Capital’s Role In Developing Next-Generation Biologics: An Interview With Takeda Research Investment’s Graeme Martin (part 2 of 2)
Corporate Venture Capital’s Role In Developing Next-Generation Biologics: An Interview With Takeda Research Investment’s Graeme Martin (part 2 of 2)
Takeda And Alnylam Highlight Keys To Successful Negotiation And Collaboration At BIO Conference
Takeda And Alnylam Highlight Keys To Successful Negotiation And Collaboration - BIO Conference
Kyowa Hakko Kirin Licenses Anti-LIGHT MAB To Sanofi-Aventis
Kyowa Hakko Enters Antibody Space With Alnylam RNAi RSV Therapy
Join The Club: Alnylam Signs On Takeda In RNAi Platform Deal
Join The Club: Alnylam Signs On Takeda In RNAi Platform Deal
Advertisement
UsernamePublicRestriction

Register

SC071192

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel